

INDEX

| | |
|----------------------------------------|-------|
| LIST OF ABBREVIATIONS | XXIII |
| LIST OF FIGURES..... | XXVII |
| LIST OF TABLES..... | XXXI |
| I. INTRODUCTION..... | 1 |
| 1. CANCER..... | 3 |
| 1.1. CONCEPT | 3 |
| 1.2. MOLECULAR BIOLOGY | 3 |
| 2. LUNG CANCER..... | 6 |
| 2.1. EPIDEMIOLOGY..... | 6 |
| 2.2. ETIOLOGY | 7 |
| 2.3. DIAGNOSIS AND PROGNOSIS | 8 |
| 2.4. HISTOLOGICAL CLASSIFICATION..... | 11 |
| 2.5. MOLECULAR CLASSIFICATION | 13 |
| 2.6. TREATMENT..... | 16 |
| 3. CANCER STEM CELLS | 18 |
| 3.1. TUMOR HETEROGENEITY | 18 |
| 3.2. PROPERTIES | 21 |
| 3.3. <i>IN VITRO</i> CULTURE..... | 24 |
| 3.4. MARKERS..... | 26 |
| 3.5. SIGNALING PATHWAYS | 30 |
| 3.5.1. Notch signaling pathway | 31 |
| 3.5.2. Wnt signaling pathway..... | 35 |
| 3.5.3. Hedgehog signaling pathway..... | 39 |
| 3.5.4. Other signaling pathways..... | 42 |

| | |
|------------------------------------------------------------|-----------|
| II. OBJECTIVES..... | 45 |
| | |
| III. MATERIALS & METHODS..... | 49 |
| | |
| 1. MATERIALS | 51 |
| 1.1. PATIENTS AND SAMPLES..... | 51 |
| 1.1.1. PRIMARY CULTURE ESTABLISHMENT..... | 53 |
| 1.2. CELL LINES | 54 |
| 1.3. ANIMALS..... | 55 |
| | |
| 2. METHODS | 56 |
| 2.1. CELL PROLIFERATION AND INVASION ANALYSIS..... | 56 |
| 2.1.1. GROWTH CURVES | 56 |
| 2.1.2. CITOTOXICITY ASSAYS | 56 |
| 2.1.3. CELL INVASION ASSAYS AND TIME-LAPSE VIDEO RECORDING | |
| | 57 |
| 2.2. NUCLEIC ACID ANALYSIS | 57 |
| 2.2.1. RNA AND DNA ISOLATION | 57 |
| 2.2.2. DETERMINATION OF THE MUTATIONAL STATUS | 58 |
| 2.2.2.1. DETECTION OF EGFR MUTATIONS..... | 58 |
| 2.2.2.2. DETECTION OF KRAS MUTATIONS..... | 59 |
| 2.2.3. QUANTIFICATION OF GENE EXPRESSION | 61 |
| 2.2.3.1. REVERSE TRANSCRIPTION | 61 |
| 2.2.3.2. QUANTITATIVE REAL TIME PCR | 61 |
| 2.3. PROTEIN ANALYSIS | 64 |
| 2.3.1. IMMUNOBLOTTING | 64 |
| 2.3.2. IMMUNOFLUORESCENCE..... | 66 |
| 2.3.3. IMMUNOHISTOCHEMISTRY..... | 68 |
| 2.3. BIOINFORMATIC AND STASTITICAL ANALYSIS | 70 |

| | |
|-------------------------------------------------------------------------|------------|
| IV. RESULTS & DISCUSSION | 73 |
| 1. ESTABLISHMENT OF ADHERENT AND NON-ADHERENT CULTURES.... | 75 |
| 1.1. PHENOTYPIC CHARACTERIZATION OF PRIMARY CULTURES..... | 81 |
| 1.1.1. SELF-RENEWAL, PROLIFERATION AND DIFFERENTIATION CAPACITIES | 81 |
| 1.1.2. INVASION AND TUMOR INITIATION CAPACITIES..... | 83 |
| 1.1.3. RESISTANCE TO CLASSICAL CHEMOTHERAPEUTIC AGENTS. | 85 |
| 2. GENE EXPRESSION ANALYSIS..... | 87 |
| 2.1. RNA QUANTIFICATION AND QUALITY ASSESSMENT | 87 |
| 2.2. RELATIVE mRNAs EXPRESSION | 88 |
| 2.3. UNSUPERVISED PRINCIPALCOMPONENTS ANALYSIS | 93 |
| 3. PROTEIN EXPRESSION ANALYSIS | 99 |
| 3.1. IMMUNOBLOTTING | 99 |
| 3.2. IMMUNOFLUORESCENCE..... | 102 |
| 3.1. IMMUNOHISTOCHEMISTRY | 106 |
| 4. <i>IN SILICO</i> SURVIVAL ANALYSIS | 108 |
| 4.1. CLINICOPATHOLOGICAL VARIABLES | 108 |
| 4.2. INDIVIDUAL BIOMARKERS..... | 113 |
| 4.3. GENE EXPRESSION SCORE | 120 |
| 4.4. MULTIVARIATE ANALYSIS..... | 122 |
| 5. VALIDATION OF THE PROGNOSTIC GENE EXPRESSION SCORE | 124 |
| 5.1. CLINICOPATHOLOGICAL VARIABLES | 124 |
| 5.2. INDIVIDUAL BIOMARKERS..... | 130 |
| 5.3. GENE EXPRESSION SCORE | 131 |
| 6. PHARMACOLOGICAL INHIBITION OF CSCs POTENTIAL TARGETS | 133 |
| 7. INTEGRATION OF RESULTS | 135 |

| | |
|---------------------------------------------------------------------------------|-----|
| V. CONCLUSIONS..... | 139 |
| VI. REFERENCES..... | 143 |
| VII. APPENDICES..... | 179 |
| 1. SUPPLEMENTARY MATERIAL | 181 |
| 2. APPROVAL FROM THE INSTITUTIONAL ETHICAL AND SCIENTIFIC REVIEW BOARD | 183 |
| 3. FUNDING | 185 |
| 4. NATIONAL AND INTERNATIONAL CONGRESS COMMUNICATIONS . | 185 |
| 5. PUBLICATIONS | 190 |
| 6. AWARDS | 190 |